Recent Updates
Recently added Catalysts

Oculis Holding AG

OCS
OvervaluedBiotech · Clinical
FDA catalysts, PDUFA dates & pipeline intelligence
$8.34
▼ -0.32 · -3.7%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full OCS financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $8.3052W HIGH $34.48
Volume
162.06 K
Value Traded
3.65 M
Short % Float
3.21%
-2.57%Week
-26.26%1 Month
-36.58%3 Month
-69.25%6 Month
+190.78%5 Year
+190.78%All Time

Cash Data

Unlock OCS cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
483.59 M
EPS (TTM)
-2.28
P/E Ratio
-
Ent. Value
1.31 B
Total Shares
57.98 M
Float Shares
48.40 M
Insiders
21.59%
Institutions
27.66%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
NDA Submission
OCS-01
Diabetic macular edema (DME)
NDASmall MoleculesOphthalmologic System
Unlock every OCS catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

OCS Catalyst Timeline

Dated clinical, regulatory and corporate events for Oculis Holding AG

Catalyst Timeline

Dated clinical, regulatory & corporate events for Oculis Holding AG

325Total events
10Upcoming
56Tier-1 (high impact)
2022 to 2027Coverage

Upcoming catalysts 2

T1NDA Submission
Subscribe to view catalyst details
OCS-01Filed
T2IND Submission
Subscribe to view catalyst details
Privosegtor

Event history 50

●R&D DayPresentation
Oculis to sponsor Neuro-Ophthalmology Subspecialty Day at AAO 2026 Annual Meeting
source ↗
●Oral PresentationlicaminlimabPresentation
Oculis CEO to present Licaminlimab at Eyecelerator @ AAO 2026
TNFR1-mediated dry eye diseasesource ↗
▲Partnership / LicenseCorporate
Oculis partners with National MS Society Campaign to End MS as Vision industry partner
multiple sclerosissource ↗
●Management ChangeCorporate
Lionel Carnot resigns from Oculis Board of Directors
source ↗
▲First Patient DosedPrivosegtorTrial
First patient treated in PIONEER-1 registrational trial
optic neuritissource ↗
▲Partnership / LicensePrivosegtorCorporate
Oculis signs asset purchase agreement with Accure Therapeutics for Privosegtor
source ↗
▲FDA Feedback ReceivedPrivosegtorFDA Meeting
Positive FDA pre-IND feedback for Privosegtor in acute MS relapses
acute MS relapsesource ↗
●Trial InitiationPrivosegtorTrial
PIONEER-1 clinical site activation advancing as planned
optic neuritissource ↗
▲FDA Feedback ReceivedPrivosegtorFDA Meeting
FDA Division of Neurology provided guidance that no additional preclinical studies required ahead of IND submission for Privosegtor in acute MS relapses
acute multiple sclerosis relapsessource ↗
●Enrollment UpdatelicaminlimabTrial
PREDICT-1 enrollment >45% patients randomized, all planned sites activated
dry eye diseasesource ↗
Unlock the full OCS catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How OCS actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-06-30OCS-01 (dexamethasone eye drop) Phase 3 data readout Phase 3
Unlock 2 more OCS historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

C42 / 100
Pipeline Score
$315M
Pipeline Value
Overvalued
Valuation Signal
6
Drugs Scored
0.7x
rNPV / MCap
Top 35%
Micro Cap
(rank 232 of 660)
Percentile Rank
Oculis Holding AG carries a moderate pipeline score (42/100), with $1.0B risk-adjusted pipeline value, led by Privosegtor in Optic Neuritis (Phase 3).
Showing 1 of 6 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Privosegtor Small moleculeNCT07623668Optic NeuritisPhase 3 RECRUITING 210Dec 1, 2028
Unlock the OCS pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every OCS program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Privosegtor
BreakthroughPriorityOrphan
optic neuritisPhase 22026-06-11Positive results from the ACUITY Phase 2 trial showed Privosegtor’s neuroprotective potential, as evidenced by improvements in visual function, corroborated by anatomical preservation of the retina (GCIPL and RNFL layers) and reduced neurofilament levels in the blood after an acute episode of optic neuritis.Read MoreOculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026Read More
Scroll for more · summaries link to the source press release
Unlock every OCS trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock OCS insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
John SmithCEOBuy 50,000 150,000 held$45.50 01/10/2026
Unlock the full OCS insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in OCS

Fund % of Portfolio Current MV Shares Owned Activity
PERCEPTIVE ADVISORS LLC 0.2 % (-33.3 %) 11.22 M 808.83 K 63.79% ( 315.00 K)
Unlock every fund holding OCS
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in OCS
Shares held by hedge funds each quarter, and who bought or sold.

OCS Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2027-02-19
Unlock OCS option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live OCS option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock OCS options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How OCS ranks across every disease it competes in

Competitive Position is a premium feature
See how OCS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

OCS News

OCS
Oct 8, 2026
OCSGeneral
▼ -3.7%today

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Oculis has published a notification regarding the vesting and settlement of Restricted Stock Units (RSUs) for a member of its Executive Committee and Board of Directors. This transaction, involving Riad Sherif, took place on October 5, 2026. The notification underscores the company's commitment to transparency in its managerial activities.

Read more →
OCS
Oct 7, 2026
OCSConferences/Events
▼ -3.7%today

Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day

Oculis Holding AG will present Licaminlimab at Eyecelerator @ AAO 2026, showcasing its potential in treating TNFR1-mediated dry eye disease. The company is also sponsoring the Neuro-Ophthalmology Subspecialty Day at the AAO Annual Meeting. The upcoming topline results from the PREDICT-1 trial are anticipated by year-end, which could significantly impact treatment approaches.

Read more →
OCS
Oct 1, 2026
OCSGeneral
▼ -6.2%on this news

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

Oculis Holding AG has partnered with the National Multiple Sclerosis Society to launch a five-year campaign aimed at accelerating research and improving care for multiple sclerosis (MS) patients. This collaboration will focus on the development of Privosegtor, a potential neuroprotective therapy for optic neuritis and acute MS relapses. The campaign includes various programs to engage stakeholders in the MS community.

Read more →
OCS
Sep 30, 2026
OCSGeneral
▼ -6.2%on this newsshared move

Oculis Announces Resignation of Lionel Carnot from Board of Directors

Oculis Holding AG announced the resignation of director Lionel Carnot from its Board of Directors, effective immediately. Carnot has served since 2017 and expressed gratitude for his time with the company. His departure is a personal decision and not due to any disagreements. The board will now consist of eight members as Oculis seeks a successor.

Read more →
OCS
Aug 24, 2026
OCSPhases

First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis

Oculis Holding AG has initiated the PIONEER-1 registrational trial, marking a significant milestone in evaluating Privosegtor for optic neuritis. This trial follows positive Phase 2 data and aims to establish Privosegtor as a potential neuroprotective therapy. The study will assess the drug's efficacy and safety, with promising implications for broader neurological applications.

Read more →
OCS
Aug 13, 2026
OCSGeneral

Oculis acquires development and commercial rights to Privosegtor

Oculis has successfully acquired the development and commercial rights to Privosegtor. This acquisition is expected to strengthen Oculis's product offerings and market presence. The move indicates a strategic expansion aimed at enhancing their portfolio and potentially increasing revenue opportunities.

Read more →
OCS
Aug 10, 2026
OCSGeneral

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company

Oculis has signed an asset purchase agreement with Accure Therapeutics to acquire worldwide rights to Privosegtor, a promising neuroprotective therapy. This strategic move allows Oculis to terminate its existing license agreement with Accure, enhancing its potential for economic upside. The acquisition includes an upfront payment and shares, with expected closings in early 2027. Privosegtor is currently advancing through key regulatory trials.

Read more →
OCS
Aug 6, 2026
OCSGeneral

Oculis Reports Q2 2026 Financial Results and Provides Company Update

Oculis reported its Q2 2026 financial results, highlighting progress in its neuro-ophthalmology pivot, particularly with Privosegtor in the PIONEER program and Licaminlimab in the PREDICT-1 trial. The company has received positive FDA feedback and is well-funded to continue its development efforts. However, it has decided not to pursue an FDA filing for OCS-01 in diabetic macular edema.

Read more →
OCS
Aug 6, 2026
OCSFDA Updates

FDA feedback supports new testing path for therapy in MS relapses

The FDA has provided feedback that supports a new testing pathway for a therapy aimed at treating relapses in multiple sclerosis (MS). This development is seen as a positive step towards enhancing treatment options for patients. The feedback may facilitate further clinical testing and regulatory processes for the therapy.

Read more →
OCS
Aug 3, 2026
OCSFDA Updates
▲ +5.1%on this newsshared move

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

Oculis announced positive FDA pre-IND feedback for Privosegtor, a novel neuroprotective candidate aimed at treating acute multiple sclerosis relapses. The FDA confirmed that existing data can be used for an IND application, which is planned for submission in Q4 2026. This development supports Oculis's strategy to address significant unmet needs in neuro-ophthalmology.

Read more →
OCS
Jul 2, 2026
OCSConferences/Events

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

Oculis Holding AG will participate in the Piper Sandler Virtual Ophthalmology Conference on July 10, 2026. The company plans to discuss its late-stage portfolio, including Privosegtor, a neuroprotective candidate with FDA Breakthrough Therapy designation, and Licaminlimab, a topical anti-TNFα for dry eye disease. The conference will also allow for one-on-one meetings with investors.

Read more →
OCS
Jun 11, 2026
OCSConferences/Events

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

Oculis Holding AG will present its investigational drug Privosegtor at the Clinical Trials at the Summit 2026. The presentation will detail the drug's development as a potential neuroprotective therapy for optic neuritis, following positive Phase 2 trial results and regulatory designations. The event will take place in Las Vegas on June 12-13, 2026.

Read more →
OCS
Jun 9, 2026
OCSPhases

Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease

Oculis has announced the randomization of the first patient in the PREDICT-1 trial, which is the first genotype-based registrational study for dry eye disease (DED). The trial aims to evaluate the efficacy of Licaminlimab, a precision medicine targeting the TNFR1 genotype. With a significant unmet need in DED treatment, Licaminlimab could offer a targeted solution for patients who currently face high discontinuation rates with existing therapies.

Read more →
OCS
Jun 8, 2026
OCSConferences/Events

Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference

Oculis Holding AG will participate in the 47th Annual Goldman Sachs Global Healthcare Conference, where management will discuss their late-stage portfolio. Key highlights include Privosegtor, a neuroprotective candidate with Breakthrough Therapy designation, and Licaminlimab, a topical anti-TNFα for dry eye disease. The company aims to address significant unmet medical needs in ophthalmology.

Read more →
OCS
Jun 1, 2026
OCSPhases
▼ -36.1%on this news· ran to -48% by day 3shared move

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

Oculis recently announced the topline results from its Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema. Although the trials showed significant reduction in retinal thickness, the primary endpoints related to best corrected visual acuity were not met. As a result, the company has decided against pursuing an FDA filing for the drug in this indication. Oculis will instead focus on its ongoing PIONEER and PREDICT-1 programs while capitalizing on its strong financial position.

Read more →

About Oculis Holding AG

60 employees oculis.com
BIOPHARMAWATCH ELITE PLUS
Trade the next OCS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime